There have been simply no new treatments for Alzheimers disease.

But beyond that symptomatic stage mildly, Aisen argued that researchers should go following the disease even before any medical symptoms appear. Recent research have revealed that there are signals of Alzheimer’s, which may be detected by measuring particular proteins or taking images of the brain, even before people or their doctors know anything is wrong. We would like to move to the main point where function is intact and there are no clinical symptoms, said Aisen. We believe this represents a very promising people for clinically meaningful treatment... Actavis seeks FDA advertising approval for Ambrisentan Tablets, 5 mg and 10 mg Actavis plc today confirmed that it has filed an Abbreviated New Medication Application with the U.S. Food and Drug Administration seeking acceptance to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Sciences, Inc. Gilead Sciences, Inc. On April 1 and Royalty Pharma Collection Trust filed match against Actavis, 2015 in the U.S.